Acurx Pharma Q3 net loss narrows to $2 mln
I'm PortAI, I can summarize articles.
Acurx Pharma reported a Q3 net loss of $2 million, with an EPS of -$1.23. R&D expenses fell to $0.4 million due to reduced manufacturing and consulting costs. The company completed a 1-for-20 reverse stock split to regain Nasdaq compliance. Analysts maintain a "buy" rating on the stock, with a median 12-month price target of $30.50, representing an 81.7% upside from its last closing price of $5.58.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments